Cointime

Autobahn Therapeutics

company

About

Autobahn Therapeutics is a developer of regenerative medicines to restore hope for people affected by CNS disorders.

  • 1 - 10

Highlights

Total Funding Amount
$108.70M
Funding Rounds
2
Investors
1

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$32.70M
Industries
Biotechnology,Health Care,Life Science,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders. Autobahn is leveraging a deep understanding of validated human biology coupled with its brain-targeting chemistry platform to develop thyroid hormone receptor beta agonist therapies that harness the regenerative power of the human body. The company’s pipeline is led by ABX-002 for the treatment of multiple sclerosis and adrenomyeloneuropathy (AMN), a rare genetic disorder. Autobahn Therapeutics is based in San Diego.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$108.70M
Autobahn Therapeutics has raised a total of $108.70M in funding over 2 rounds. Their latest funding was raised on Sep 8, 2022 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 8, 2022 Series Unknown $32.70M 1 — — Detail
Jun 11, 2020 Series B $76M 1 ARCH Venture Partners — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Autobahn Therapeutics is funded by 1 investors. ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners — Series Unknown
Cointime
Chủ Đề
Công Ty